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The course of melanogenesis in (malignant) melanocytes is 
determined by several relatively independent metabolic proc­
esses such as tyrosine uptake and compartmentation, the ac­
tivity of tyrosinase, and the capacity of melanosomes to pro­
duce and store melanin. There is experimental evidence that 
tyrosine is transported across the cell membrane with aNa + -
independent L transport system. Tyrosine designated for mel­
anogenesis is probably localized in compartments different 
from those for protein synthesis. The maturation and subse­
quent activation of tyrosinase occurs primarily in the Golgi­
associated endoplasmatic reticulum and coated vesicles. In 
these locations, the interaction between tyrosine and tyrosin­
ase has some limitations because no melanin polymer can be 
detected in these structures. Nevertheless, the coated vesicles 
were shown to contain unpolymerized monomeric indols. 
Individual skin types differ in their ability to produce mature, 
fully pigmented, melanosomes. Whereas eumelanin content 
in melanocytes corresponds to the phenotypic appearance of 
the skin, the formation of pheomelanin varies considerably. 
M elanogenesis is a metabolic process that. in humans seems to have one main aim: to produce rapidly a light absorbing material to protect the body against harmful effects of ultraviolet light. It is noteworthy that the chain of melanogenic reac­
tions begins and ends with relatively stable compounds. namely 
tyrosine and melanin. whereas the intermediates are mostly reac­
tive. unstable substances. 
For a straightforward course of melanogenesis several key steps 
are of importance: the uptake and compartmentation of tyrosine. 
the activity of correctly localized tyrosinase, the sufficient capacity 
of melanosomes to store melanin. and the ability to transfer these 
particles to surrounding keratinocytes. The efficacy of these individ­
ual. mostly mutually independent. steps is under genetic control. 
TYROSINE TRANSPORT 
Tyrosine belongs to the amino acids that are transported across the 
cell membrane with the so-called L (leucine) system. This Na+­
independent and pH-insensitive system is regarded as an exchange 
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5,6DHI: 5,6-dihydroxyindole 
5,6DHI2C: 5,6-dihydroxyindole-2-carboxylic acid 
5-S-CD: S-S-cysteinyldopa 
5-S-GD: S-S-glutathionyldopa 
GERL: Golgi-associated endoplasmic reticulum 
Precursors of pheomelanin, such as glutathione and cysteine, 
are responsible for scavenging potentially toxic quinoid prod­
ucts of melanogenesis that escape from melanogenic com­
partments. Pheomelanogenesis can therefore be considered 
as one of the protective mechanisms of melanocytes. Signifi­
cant leakage of reactive intermediates of melanogenesis may 
occur from aberrant melanosomes and explain the frequent 
incidence of necrosis in melanoma tissue. The presence of 
O-methylated derivatives of S,6-dihydroxyindole (S,6DHI) 
and S,6-dihydroxyindole-2-carboxylic acid (S,6DHI2C) in 
medium of melanoma cell cultures gives evidence of intra­
cellular O-methylating ability. The O-methylation of o-di­
hydroxyphenols and indols by catechol-O-methyltransferase 
localized in microsomes and cytoplasma prevents their oxi­
dation to reactive quinones. It is suggested, however, that this 
protective mechanism can be unreliable because catechol-O­
methyltransferase can be inactivated by its oxidated sub­
strates. ] Invest Dermato11 00:1628 -1658, 1993 
transporter between extra- and intracellular amino acids possessing 
long branched or aromatic side chains [1]. In B-16 mouse melanoma 
cells. Saga and Shimojo found KM value for tyrosine uptake to be 
75 p.M [2]. This was in the range reported for tyrosine transport in 
neuroblastoma cells and close to that for leucine uptake in 3T3 
mouse cells. suggesting the presence of a similar transport system in 
all these cell types. In another set of experiments the same authors 
found that the L system transport of tyrosine across the membrane 
was stimulated by theophylline. but this stimulation could be par­
tially inhibited by cycloheximide. This suggested that the induction 
of system L requires protein synthesis. probably the generation of 
transport proteins [3]. 
That the tyrosine uptake and melanogenesis are not fully depen­
dent on each other was demonstrated in melanocytes from hair 
bulbs of type I1a (tyrosinase-positive) oculo-cutaneous albinism. 
King and Olds showed that these melanocytes. although not pro­
ducing melanin. took up normal amounts of tyrosine [4]. The au­
thors measured tyrosine uptake by incubating fresh anagen hair­
bulbs in 14C-tyrosine dissolved in a buffer with cycloheximide and 
catalase. It is noteworthy that they found the highest tyrosine up­
take in red-haired subjects. Thus. the uptake of tyrosine does not 
seem to be directly dependent on its utilization for eumelanin syn­
thesis. 
In another interesting paper Farishian and Whittaker reported 
that. in their hamster melanoma model. tyrosine uptake could be 
influenced by the external concentration of tyrosine; however. the 
melanocytes starved of this amino acid were still able to synthesize 
approximately 30% of the amount of melanin when compared with 
non-starving controls [5]. The authors suggest that tyrosine is at 
least partly compartmentalized specifically for melanogenesis and 
that this localization differs from that for protein synthesis. 
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TYROSINASE 
The dynamics of melanogenesis will undoubtly depend on the activ­
ity and compartmentation of tyrosinase. The maturation and activa­
tion of this enzyme was shown to occur primarily due to a glycosy­
lation process in the Golgi-associated endoplasmic reticulum 
(GERL) and the coated vesicle system [6,7]. Glycosylated tyrosinase 
is then transported to pre-melanosomes in coated vesicles and the 
vesicles are present in the melanosomes as vesiculo-globular bodies. 
In this location, tyrosinase and tyrosine apparently do not interact 
fully because no electron-dense melanin polymer can be found in 
these subcellular structures. Another possibility is that these organ­
elles contain an inhibitor of polymerization. This interesting point 
needs further elucidation, because Hatta and co-workers reported 
the presence of substantial amounts of unpolymerized 5,6-dihy­
droxyindole (5,6DHI) and 5,6-dihydroxyindole-2-carboxylic acid 
(5,6DHI2C) within coated vesicle fractions of pigment cells [8]. 
Imokawa subsequently showed that the transfer of tyrosinase to 
pre-melanosomes could be enhanced by theophylline. However, 
the enhancement could be effectively diminished by glutathione, 
causing a defect in intracellular translocation of this enzyme. At the 
same time, the appearance of membrane-bound T3 tyrosinase was 
blocked. Despite the melanization defect, the electron microscopic 
status of unmelanized pre-melanosomes appeared to be undisturbed 
[9]. 
The production of highly reactive melanin intermediates repre­
sents a potential threat to the cell. That is why melanin formation 
cannot take place in the cytoplasm but is confined to special mem­
brane-limited organelles that prevent the toxic intermediates from 
spreading inside the cell. Abnormal compartmentation of tyrosinase 
could result in intracellular damage. Such an event could fit with the 
auto-destruction theory on vitiligo. Interestingly, in recent work by 
Boissy and co-workers, using a vitiligo mouse model, some aberrant 
dopa-positive structures and dilated rough endoplasmic reticulum 
have been reported [10]. 
MELANOSOMES 
As shown in the above-quoted paper by King and Olds [4], the 
presence of tyrosinase and its substrate does not guarantee the nor­
mal synthesis of melanin pigment. One of the still poorly under­
stood factors is the ability to generate and the capacity to store 
melanin inside melanosomes. Individual skin types differ not only 
by the ratio between pheomelanin and eumelanin but also in their 
ability to produce mature, fully melanized, melanosomes. The mela­
nocytes in pigmented subjects, such as Mongoloids and Negroids, 
contain more melanosomes-at least five times more in Mongo­
loids and eight to ten times more in Negroids than in fair-skinned 
Caucasoids. Melanosomes in these pigmented persons are more me­
lanized, are larger in size, and show more clearly the presence of 
electron-lucent bodies than those found in fair-skinned Caucasoid 
subjects [11]. 
In principle, two types of melanosomes have been described: a) 
spherical melanosomes, which are often found in structures produc­
ing pheomelanins such as hair follicles in red-haired persons [12], 
and b) ellipsoidal-lamellar (filamentous) melanosomes, which are 
more characteristic of melanocytes preferentially producing eume­
lanin. Similar two types of melanosomes can be isolated from B-16 
and Harding-Passey mouse melanomas. Whereas B-16 melanoma 
produces brown-black ellipsoidal-lamellar melanosomes, the Hard­
ing-Passey tumor synthesizes reddish or light-brown spherical­
granular particles. It is, therefore, not surprising that these tumors 
have been utilized as models for the study of melanosomes. Jimbow 
and co-workers studied protein and lipid composition of these two 
types of melanosomes to elucidate whether there are any features of 
melanosomal proteins and lipids related to melanosomal morphol­
ogy [13]. They found that the lipid content in B-16 melanosomes 
was much higher than that in melanosomes isolated from Harding­
Passey melanomas. Moreover the study indicated that the core of 
both types of melanosomes was relatively poor in phospholipids 
and rich in polypeptides that were markedly different with re-
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spect to their composition. On the other hand, the outer surface 
fraction of both tumor melanosomes were similar in polypeptide 
composition, but quite rich and different in relative phospholipid 
content. These facts may suggest that the outer surface of melano­
somes is structurally similar, but functionally different between 
B-16 and Harding-Passey melanoma and that the protein compo­
nent, rather than phospholipids, is responsible for the structural 
difference of the melanosomes. Using the same model system, Ito 
and co-workers investigated free and protein-bound forms of dopa 
together with 5-S-cysteinyldopa (5-S-CD) and 5-S-glutathionyl­
dopa (5-S-GD). The only difference they found was in the content 
of free 5-S-GD. Whereas lightly pigmented Harding-Passey mela­
noma with spherical-granular melanosomes contained significant 
amounts of this thioether, the concentrations of 5-S-GD in the 
darkly pigmented B-16 tumor was hardly measurable. The authors 
concluded that the striking difference in the color of melanosomes 
seems to be related primarily to the content and not to the type of 
melanin pigment [14]. 
It is not completely clear what role should be ascribed to thio­
compounds, such as glutathione and cysteine. As mentioned above, 
glutathione is able to inhibit the translocation process of tyrosinase. 
Also, this compound can function as an inhibitor of tyrosinase and 
plays an important part in the detoxification of reactive quinone 
intermediates. That is why glutathione may occupy a pivotal posi­
tion in the regulation of melanin synthesis. Moreover, this sub­
stance may be responsible for the resistance of melanoma cells to 
different cytostatics [15]. 
The ability of melanosomes to store melanin may therefore not 
only be dependent on the internal structure and composition of 
melanosomes but on the presence of compounds, such as glutathi­
one, that may react with melanin precursors and prevent them from 
binding on the melanosomal matrix. Carstan and co-workers mea­
sured dopa and different thioethers including 5-S-CD and 5-S-GD 
in homogenates of cultured human melanoma cells and culture 
media [16]. In the culture medium the concentration of 5-S-GD was 
found to be half that of the cells whereas the concentration of 
5-S-CD outside the cells was only 2% of the intracellular concen­
tration. This could support the idea that glutathione might serve as a 
rapid transport mechanism to remove potentially toxic o-quinones 
from the cell. 5-S-GD was further found to be converted to black 
melanin, possibly via conversion to 7-S-glutathionyl-5,6-dihy­
droxyindole and subsequent polymerization [17]. Although the exis­
tence of this indole derivative was confirmed by in vitro synthesis 
[18] its identification in vivo has not yet been reported. 
EUMELANIN-RELATED COMPOUNDS 
Despite the fact that eumelanin monomers, namely 5,6DHI and 
5,6DHI2C, are more reactive than their pheomelanin partners, and 
that their polymerization rate can be higher, not all of them partici­
pate in the polymerization process (Fig 1). Some molecules escape 
from the melanogenic compartments, leave the cell, and are trans­
ported in blood and excreted in urine. The presence of so-called 
urinary melanogens has been recognized for more than a century; 
however, their structure was not elucidated until much later [19-
23]. It was shown that the entire class of indolic melanin-related 
compounds consisted of two eumelanin precursors and their 0-
methylated metabolites. 5,6DHI itself was detected in vivo for the 
first time in 1981 [20]. Three years later its conjugated form, iso­
lated from melanotic urine, was identified [24]. The question re­
mains, however, why some eumelanin monomers are excluded 
from melanin generation and in which compartments they are pro­
duced. It is extremely improbable that free 5,6DHI and 5,6DHI2C 
arise from the melanin polymer itself. It is more likely that they leak 
out of coated vesicles and/or (pre)melanosomes. At any rate, their 
presence and easy oxidizability to quinones and semiquinones may 
threaten cellular metabolism. Such a situation can lead to damage or 
even death of melanocytes, a phenomenon well known from viti­
ligo, halo nevi, or spontaneous melanoma regression. Borovansky 
and co-workers have recently demonstrated the presence of abnor­
mal and incomplete melanosomes in different melanoma cells [25]. 
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Figure 1. Overall summary of the metabolism of melanogenesis inter­
mediates. T, tyrosinase; DOPA, 3,4-dihydroxyphenylalanine; 5,6DH-IN­
DOLES, 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic 
acid; INDOLE-5,6-QUINONES, indole-5,6-quinone and indole-5,6-qui­
none-2-carboxylic acid. 
They conclude that significant leakage of reactive melanin precur­
sors (including free radical species) may occur from the aberrant 
melanosomes and that this may explain the frequent occurrence of 
necrosis in melanoma tissue. Several authors have rc:l'orted vitiligo 
to be a good prognostic sign in melanoma patients l26,2?]: .
Lerner 
and Kirkwood have suggested that the melanocytes of Vltlhgo pa­
tients or persons with a genetic background for vitiligo were predis­
posed to undergo malignant transformation [28]. This is not unreal­
istic if we consider that leaking reactive melanin precursors are able 
to interact with genetic material [29,30]. 
The endangerment of melanocytes by their own toxic metabo­
lites must be counteracted by a possession of protective mechanisms. 
Among those, glutathione has already been mentioned. This com­
pound is synthesized i� v�lly all living ce�l� and plays � very 
important role as an antiOX1dant defense. In
.
a�ditlon, glutat�lOne 1S 
an important conjugator of the electroph1hc groups of different 
molecules. In melanocytes, this conjugation function provides an 
important detoxification mechanism. From this point of view, it is 
considered by some that pheomelanogenesis results merely from 
scavenging of intracellular toxic quinones. As shown in a recent 
paper by Thody et aI, the concentration of pheomelanin in the 
epidermis of skin types I - III varies considerably and s�ows no rela­
tionship to skin type [31]. Even after psoralen + ultrav10let A treat­
ment, the increase of pheomelanin was shown to be unrelated to 
skin type. It is highly likely that pheomelanogenesis is the result of a 
process of intracellular detoxification that reflects primarily the ve­
locity of melanogenesis and the storage capacity of melanosomes. In 
persons with apparently limited capacity to store melanin (skin type 
I) pheomelanogenesis may prevail. 
CATECHOL-O-METHYLTRANSFERASE 
Already in 1963, Axelrod and Lerner demonstrated that catechol­
O-methyltransferase (COMT) from the rat liver and dried hamster 
melanoma was able to methylate both 5,6DHI and 5,6DHI2C [32]. 
Four years later, Duchon and Matous reported on the identification 
of O-methylderivatives of 5,6DHI2C in urine of patients with mel­
anoma [19] and, several years later, other O-methylated derivatives 
were found in urine [20-23]. However, the idea that O-methyla­
tion might represent an important intracellular protective mecha-
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Figure 2. A possible mechanism of COMT inhibition by 5,6-dihydrox· 
yindole (5,6DHI). Oxidation of 5,6DHI gives rise to indole-5,6-quinone, 
which can link covalently to amino-or thiogroup of the COMT active 
center. SAM: S-adenosylmethionine (methyl donor) . 
nism in (malignant) melanocytes had not been put forward until the 
O-methylderivatives of 5,6DHI and 5,6DHI2C were identified in 
the medium of melanoma cell culture [33]. 
The recent investigation of COMT activity with the use of two 
different substrates, namely 3,4-dihydroxybenzoic acid and 
5,6DHI2C, revealed that the enzyme has a higher affinity to the 
latter compound. In case of COMT from a human melanoma cell 
line, the KM value for 5,6DHI2C was found to be more than ten 
times lower, underlining the idea of the physiologic relationship of 
both components in (malignant) melanocytes [34]. 
COMT is known to play an important role in catabolism of 
catecholamine neurotransmitters, catechol estrogens, and xenobiot­
ics. In melanocytes, an additional protective function is ascribed to 
this enzyme. The O-methylation of o-dihydroxyindolic and pheno­
lic compounds by COMT prevents their oxidation to reactive qui­
nones and their subsequent polymerization. When localized in the 
vicinity of melanogenic process, COMT might even play a part in 
the regulation of melanogenesis. Our recent experiments aimed at 
subcellular localization of COMT in hamster melanoma revealed 
that this enzyme is localized particularly in the microsomal fraction 
and cytosol [35]. This is in agreement with reports from the litera­
ture showing that in tissues like human brain, liver, or some blood 
cells, COMT could also be found preferentially in these two loca­
tions. The comparison of the COMT activity in melanotic and 
amelanotic hamster melanoma disclosed consistent differences in 
the activity of the enzyme. The fractions from the amelanotic 
tumor exhibited always higher COMT activities than did the frac­
tions from the pigmented melanoma tissue. Although there is no 
certain explanation for this phenomenon, one should consider a 
possibility that COMT from the pigment-forming cells could be 
partly inactivated by reactive indolic substrates, particularly 5,6DHI 
(Fig 2). This would be in agreement with the paper by Borchard and 
Bhatia who demonstrated that 5,6DHI and some of its derivatives 
could inactivate purified rat liver COMT, apparently by covalent 
linkage of quinoid oxidation products to active centrum of the en­
zyme [36]. Catechol-o-methyltransferase could be then considered 
as a vulnerable factor in intracellular defense mechanisms of (malig­
nant) melanocytes. 
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